Skip to main content
OpenTrials
Completed

NCT Number: NCT00711347

Intraoperative Floppy Iris Syndrome

An assessment of the surgical performance of DisCoVisc compared to Healon5 during cataract surgery with intraocular lens implantation where miotic/small pupils or intraoperative Floppy Iris Syndrome exists.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Contact Alcon Call Center for Study Locations

Fort Worth, Texas, 76134, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • diagnosed with floppy iris syndrome
  • operable bilateral cataracts

Exclusion criteria

  • Intraocular Pressure (IOP) > 21mmHg
  • ocular inflammatory disease
  • systemic or ocular diseases affecting Endothelial Cell Count

Treatment and study plan

DiscoVisc

Device

Use of Alcon's DisCoVisc Ophthalmic Viscosurgical Device(4% sodium chondroitin sulfate, 1.65% sodium hyaluronate) during cataract surgery with intraocular lens implantation.

Healon5

Device

Use of Abbott Medical Optics (AMO) Healon5 Ophthalmic Viscosurgical Device (2.3% Sodium Hyaluronate) during cataract surgery with intraocular lens implantation.

Primary outcomes

  1. Corneal Endothelial Cell Loss

    Time frame: 1 month

    Endothelial cell loss/gain is measured by comparing the preoperative assessment of endothelial cell density against postoperative measurements. Measurements are made with a specular microscope, which takes a picture and numbers endothelial cells. This endpoint compares the assessment done at 1 month against the assessment done at baseline. A negative number indicates a loss of endothelial cells, a positive number indicates a gain in endothelial cells.

Secondary outcomes

  1. Intraocular Pressure (IOP)

    Time frame: 1 Day Postoperative

    Intraocular Pressure (IOP) is assessed with a slit lamp by means of Applanation (Goldmann) tonometry. This type of tonometry uses a small probe to gently flatten part of your cornea to measure eye pressure. The pressure in your eye is measured by how much force is needed to flatten your cornea, and measured in millimeters of mercury (mmHg). Normally, IOP should be less than 21 mmHg.

  2. Aqueous Signs - Cells

    Time frame: 1 Day Postoperative

    Aqueous Cells are the foggy appearance given by protein that has leaked from inflamed blood vessels. This is evaluated by the surgeon one day post surgery and rated on the following scale: None, 0: 1-5 cells, 1: 6-15 cells, 2: 16-30 cells, 3: >30 cells

  3. Aqueous Signs - Flare

    Time frame: 1 Day Postoperative

    Aqueous Flare refers to individual inflammatory cells. Aqueous flare is evaluated by the surgeon one day after surgery and rated on the following scale:

    0:No-Visible flare when compared with the normal eye.

    • Mild-Flare visible against dark papillary background but not visible against iris background.
    • Moderate-flare is visible with the slit-lamp beam aimed onto the iris surface as well as the dark papillary background.
    • Severe-Very dense flare. May also present as a hazy appearance of anterior segment structures when viewed with low power magnification of the slit-lamp.
  4. Aqueous Signs - Edema

    Time frame: 1 Day Postoperative

    Aqueous signs refers cornea edema evaluated by the surgeon one day after surgery. Corneal edema is evaluated by the following scale:

    0 = none

    • = mild - slight localized or generalized edema
    • = moderate - significant localized or generalized edema
    • = severe - advanced localized or generalized edema
  5. Surgeon Survey

    Time frame: Time of Surgery

    Survey completed by the surgeon to evaluate use of the product during surgery. Responses are rated on the following scale and the means of the responses are reported:

    Overall surgical difficulty: 1 - very easy; 2 - easy; 3 - neither easy nor difficult; 4 - difficult; 5 - very difficult

    Satisfaction with performance: 1 - strongly disagree; 2 - disagree; 3 - undecided/neutral; 4 - agree; 5 - strongly agree

    Ability to expand pupil: 1 - not effective; 2 - moderately effective; 3 - very effective

Sponsors and collaborators

Lead sponsor

Alcon Research

Industry

Registry information

Important dates

Study start
2007
Primary completion
2008
Study completion
2008
First posted
Jul 8, 2008
Registry last updated
Aug 10, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.